Skip to main content
. 2018 Jun;18(3):245–250. doi: 10.7861/clinmedicine.18-3-245

Fig 1.

Fig 1.

Pathophysiology and treatment options in NAFLD. DM = diabetes mellitus; FXR = farsinoid X receptor; HCC = hepatocellular carcinoma; LPS = lipopolysaccharide; NAFLD = non-alcoholic fatty liver; NASH = non-alcoholic steatohepatitis; PNPLA3 = patatin-like phospholipase domain-containing protein 3; TLR = toll-like receptor